GSK and Avalon announce the first startup fruit of $495m biotech alliance announced in April.

Pharmaceutical giant GlaxoSmithKline (GSK) and US-based VC Avalon Ventures have announced the creation of the first of up to ten San Diego-based biotech firms as part of a $495m alliance signed in April.

Sitari Pharmaceuticals, which is using technology licensed from Stanford University, will receive a total of $10m from Avalon and GSK to get the San Diego-based company off the ground. The company will investigate treatments for celiac disease, an autoimmune disorder which targets the small intestine.  Avalon also…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?